Eli Lilly and Company (LLY) Aktienanalyse

Unternehmensübersicht

Eli Lilly and Company operates as a leading manufacturer of human pharmaceutical products across the United States, Europe, China, Japan, and various international markets. The enterprise functions within the Healthcare sector and specifically belongs to the Drug Manufacturers - General industry, positioning it as a critical player in the global supply of essential medicines. This pharmaceutical giant employs approximately 50,000 individuals and holds a substantial market capitalization of $786.04 billion, reflecting its status as a dominant entity in the healthcare landscape. The company generates annual revenue of $65.18 billion, a figure that underscores its massive scale and significant influence within the healthcare market relative to its peers. These valuation and revenue metrics indicate that Eli Lilly commands a premium position, serving a vast customer base with a diverse portfolio of cardiometabolic health products and other therapeutic solutions.

Finanzielle Gesundheit

The company reports a trailing twelve-month revenue of $65.18 billion, with corresponding net income of $20.64 billion and an EBITDA of $31.69 billion. The substantial gap between the $65.18 billion in revenue and the $20.64 billion in net income reveals a highly efficient cost structure, allowing the firm to retain over 31% of its top-line sales as bottom-line profit. Operating with a free cash flow of $1.95 billion, the company maintains a specific level of liquidity generation that supports ongoing operations and strategic initiatives, though this figure appears lower than EBITDA due to significant capital expenditures. The gross margin stands at 83.0%, indicating strong pricing power and low variable costs typical of pharmaceutical manufacturing, while the operating margin of 44.9% demonstrates effective control over administrative and selling expenses. Furthermore, the profit margin of 31.7% confirms that the company successfully converts a significant portion of its revenue into net earnings. On the balance sheet, Eli Lilly holds $7.27 billion in cash against $43.87 billion in debt, resulting in a debt-to-equity ratio of 165.31, which suggests a leveraged capital structure reliant on creditor financing. The current ratio of 1.58 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity. Return on equity reaches an exceptional 101.2%, while return on assets sits at 19.4%, metrics that collectively reveal highly effective management in utilizing shareholder capital and total assets to generate returns.

Bewertungsanalyse

The valuation metrics show a trailing P/E ratio of 38.32 and a forward P/E of 20.86, implying that the market expects a significant acceleration in earnings growth to justify the current multiple compression or that future earnings are anticipated to nearly double. The price-to-book ratio is listed at 29.62, indicating that the stock trades at a substantial premium relative to its book value, reflecting high intangible asset value and growth expectations. Alternative valuation metrics such as the price-to-sales ratio of 12.06 and an EV/EBITDA of 25.91 suggest that investors are willing to pay a high multiple for every dollar of sales and earnings, consistent with a high-growth healthcare profile. Regarding price volatility, the stock has a 52-week high of $1133.95 and a 52-week low of $623.78, providing a clear range for historical trading behavior. The beta value of 0.43 indicates that the stock exhibits significantly lower price volatility than the broader market, suggesting it may be less sensitive to general market fluctuations compared to large-cap peers.

Growth & Income

Eli Lilly demonstrates robust expansion with a revenue growth year-over-year of 42.6% and earnings growth year-over-year of 51.4%, indicating that profitability is expanding at a faster pace than top-line sales, which implies improving operational leverage and pricing power. The company offers a dividend yield of 0.7% with a payout ratio of 26.1%, a conservative distribution level that appears highly sustainable given the robust earnings growth and high profit margins. The relatively low payout ratio ensures that a majority of earnings are retained to fund research and development rather than being distributed immediately to shareholders. Overall, the growth and income profile is characterized by double-digit earnings acceleration supported by a conservative dividend policy that balances shareholder returns with aggressive reinvestment in the business.